2020 ADA VIRTUAL PRODUCT THEATERS

Saturday, June 13, 2020

10:15 a.m.-11:00 a.m.

Enabling Telemedicine and Remote Monitoring With the Freestyle Libre 14 Day System
(This Product Theater is Pre-Recorded)

Presented by Abbott

Join us to learn about the #1 CGM worldwide† used by more than 2 million people*, the FreeStyle Libre 14-day system.

Daniel Einhorn, MD, FACP, FACE, will share how he utilizes the FreeStyle Libre 14-day system to enable diabetes management and monitoring of patients remotely. Dr. Einhorn will also share real-world telemedicine patient cases.

Presenter: Daniel Einhorn, MD, FACP, FACE
   Medical Director, Scripps Whittier Diabetes Institute
   Clinical Professor of Medicine, University of California, San Diego
   President, Diabetes and Endocrine Associates
   San Diego, CA

Location: Product Theater #1

†Data based on the number of users worldwide for FreeStyle Libre personal CGM compared to the number of users for other leading personal CGM brands.

*Data based on the number of users worldwide for FreeStyle Libre products. In the United States product is branded FreeStyle Libre 14-day System

This program is sponsored by Abbott, the speaker or speakers are presenting on behalf of Abbott and the content of the program is in compliance with applicable regulatory requirements.

10:15 a.m. 11:00 a.m.

Is It Time to Reconsider Your Treatment Strategy in Your Patients with T2D? (For non-U.S. HCPs Only)
(This Product Theater is Pre-Recorded)

Presented by Novo Nordisk

Explore efficacy and safety data for a GLP-1RA option for adults with T2D. A data review from pivotal glycemic control trials as well as cardiovascular outcomes data will be presented.

Presenter: Christoph Terkamp, MD
   Attending Physician, Division of Gastroenterology, Hepatology and Endocrinology
   Hannover Medical School University Hospital
   Hannover, Germany

Location: Product Theater #3
12:30 p.m.-1:30 p.m.

**Thinking Beyond Glycemia—The Importance of Managing Heart Failure Risks in Type 2 Diabetes**
(This Product Theater is Pre-Recorded)

*Presented by AstraZeneca*

We will examine the risk of heart failure (HF) among patients with type 2 diabetes (T2D) and explore evidence-based risk reduction strategies that you can incorporate into your practice. We will discuss the results of the DECLARE trial, the largest cardiovascular (CV) outcomes trial to study hospitalization for HF risk reduction in patients with T2D and CV disease or multiple CV risk factors. We’ll also discuss the results of the landmark DAPA-HF trial that support FARXIGA being the FIRST and ONLY FDA-approved sodium-glucose cotransporter 2 inhibitor (SGLT2) for patients with HF with reduced ejection fraction (HFrEF) with and without T2D.

**Presenter:** Serge Jabbour, MD, FACP, FACE  
Professor of Medicine  
Director, Division of Endocrinology, Diabetes & Metabolic Disease  
Sidney Kimmel Medical College at Thomas Jefferson University  
Philadelphia, PA

**Location:** Product Theater #2

12:30 p.m.-1:30 p.m.

**Are We Waiting Too Long to Start a GLP-1RA in Adult Patients with T2D? (For Non-U.S. HCPs Only)**
(This Product Theater is Pre-Recorded)

*Presented by Novo Nordisk*

This presentation provides an overview of a GLP-1RA for adult patients with T2D, including an in-depth review of head-to-head data from the clinical trial program. The results from a CVOT will also be reviewed.

**Presenter:** Adie Viljoen, MB, ChB, FCP, MD, FRCPath, MBA  
Consultant Metabolic Physician  
The Lister Hospital  
Stevenage, United Kingdom

**Location:** Product Theater #3
Sunday, June 14, 2020

10:15 a.m.-11:00 a.m.

Considerations for Glycemic Control—Choosing a Basal Insulin for Patients with Diabetes
(This Product Theater is Pre-Recorded)

*Presented by Sanofi*

**Presenter:** Helen Baron, MD, CCD  
Medical Director, Diabetes Services  
Eisenhower Diabetes and Endocrinology  
Eisenhower Medical Associates  
Rancho Mirage, CA

**Location:** Product Theater #1

10:15 a.m.-11:00 a.m.

VASCEPA® (icosapent ethyl)—Elevating the Standard of Care
(This Product Theater is Presented Live)

*Presented by Amarin*

There is an urgency to treat Persistent Cardiovascular Risk (P-CVR) as it remains high despite statin-based standard-of-care therapy in patients with elevated triglycerides. In this program, we will review data from a practice changing trial that provides a groundbreaking therapeutic option to elevate the current standard of care.

**Presenter:** Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE  
Endocrinologist  
Medical Director & Principal Investigator  
Metabolic Institute of America  
Tarzana, CA

**Location:** Product Theater #2
Understanding Chronic Kidney Disease in Type 2 Diabetes—The Risks, Recognition, and Clinical Management
(This Product Theater is Presented Live. It Will Not Be Available On Demand)
Presented by Bayer

Chronic Kidney Disease (CKD) develops in a substantial proportion of patients with type 2 diabetes (T2D) and significantly increases risk for adverse cardiovascular and renal outcomes. Multiple factors can contribute to the development and progression of CKD in T2D, although understanding of the etiology continues to evolve. The deleterious impact of CKD in T2D progresses over time, but consequences emerge in early stage disease, raising the importance of adherence to guideline recommendations for diagnostic screening, continued monitoring, and coordination of care across specialties for patients with CKD and T2D.

Presenter: Luiza Caramori, MD, PhD, MSc
Associate Professor of Medicine, Division of Diabetes, Endocrinology and Metabolism
University of Minnesota
Minneapolis, MN

Location: Product Theater #1

Break the Sequential T2DM Treatment Pattern in Adult Patients with High A1C (≥9%) on OADs, or Uncontrolled on GLP-1 Ras, and get them to Goal
(This Product Theater is Pre-Recorded)
Presented by Sanofi

Presenter: Jeremy Pettus, MD
Assistant Professor of Medicine
Division of Endocrinology
University of California, San Diego
San Diego, CA

Location: Product Theater #2
12:30 p.m.-1:30 p.m.

Renal and Cardiovascular Outcomes in Adults with Diabetic Nephropathy (i.e., DKD) and Type 2 Diabetes (U.S. Only)
(This Product Theater is Presented Live. It Will Not Be Available On Demand)
Presented by Janssen

Topics include:

- Renal and cardiovascular outcomes and overall safety profile in adults with diabetic nephropathy (i.e., diabetic kidney disease) and type 2 diabetes
- Important Safety Information, followed by a question-and-answer session

**Presenter:** Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE
Endocrinologist
Medical Director & Principal Investigator
Metabolic Institute of America
Tarzana, CA

**Location:** Product Theater #3

3:00 p.m.-3:45 p.m.

Simplifying Diabetes Management—Advancing Innovation Across Outcomes, Patient Experience, and Support with the Guardian™ Connect Continuous Glucose Monitoring (CGM) System (U.S. Only)
(This Product Theater is Pre-Recorded)
Presented by Medtronic

Please join us for a virtual product theater on Medtronic’s cutting-edge Guardian™ Connect continuous glucose monitoring (CGM) technology and the role it plays in virtual diabetes care. You will hear from Dr. Amit Bhargava, MD about real-world outcomes and case studies of patients using the Guardian™ Connect system with the Sugar.IQ™ diabetes assistant. This will be followed by a unique opportunity to observe a virtual telehealth conversation between Dr. Jason Baker, MD and his patient, Sam Talbot – as they walk you through their journey navigating diabetes management during COVID-19.

**Presenters:**

- Sean Salmon
  Executive Vice President and President
  Medtronic Diabetes

- Amit Bhargava, MD, FACSc
  The Center for Diabetes and Endocrine Health of Allegheny General Hospital

- Sam Talbot
  Celebrity Chef and T1 diabetes patient

- Jason Baker, MD
  Assistant Professor of Clinical Medicine and Attending Endocrinologist
  New York-Presbyterian/Weill Cornell Medical Center
  New York, NY

**Location:** Product Theater #2
Monday, June 15, 2020

12:30 p.m.-1:30 p.m.
Redesigning the Future of Diabetes Care with Telehealth
(This Product Theater is Presented Live)
Presented by Glooko

The current COVID-19 pandemic has significantly shifted the delivery of health care for patients around the globe. With the growing shortage of clinicians, and newly enacted social distancing guidelines, telehealth and remote patient management has emerged as a quintessential part of anywhere & anytime care.

As a digital health provider, Glooko enables telehealth by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps connected pens and activity trackers—bringing insights together in one place.

Join Glooko to discuss challenges with the sudden transition to telehealth and share best practices for providers interested in defining the new standard of care which will serve as the foundation of care for the next decade.

Presenters: Mark Clements, MD, PhD
Chief Medical Officer
Glooko
Mountain View, CA
Ryan Kuriakose, PharmD, MS
Senior Marketing Manager
Glooko
Mountain View, CA
Jeff Change
Director of Product Management
Glooko
Mountain View, CA

Location: Product Theater #2

12:30 p.m.-1:30 p.m.
Atherosclerotic Cardiovascular Disease (ASCVD) in Diabetes: Identifying High Risk and Reducing the Burden of Elevated LDL-C Levels (Coming Soon)
Presented by Novartis

Location: Product Theater #1
12:30 p.m.-1:30 p.m.

Dexcom G6 Pro—Enabling Virtual Visits with Data Driven Discussions
(This Product Theater is Presented Live)

Presented by Dexcom

Presenters: Davida Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner
Henry Ford Hospital
Detroit, MI

Daniel Katselnik, MD
Diabetes & Metabolism Specialists
San Antonio, TX

Location: Product Theater #3